For: | Liang CM, Chen L, Hu H, Ma HY, Gao LL, Qin J, Zhong CP. Chemokines and their receptors play important roles in the development of hepatocellular carcinoma. World J Hepatol 2015; 7(10): 1390-1402 [PMID: 26052384 DOI: 10.4254/wjh.v7.i10.1390] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v7/i10/1390.htm |
Number | Citing Articles |
1 |
Yafei Wang, Biao Gao, Tianyu Jiao, Wenwen Zhang, Huizhong Shi, Hao Jiang, Xuerui Li, Junfeng Li, Xinlan Ge, Ke Pan, Chonghui Li, Guankun Mao, Shichun Lu. CCL5/CCR5/CYP1A1 pathway prompts liver cancer cells to survive in the combination of targeted and immunological therapies. Cancer Science 2024; 115(11): 3552 doi: 10.1111/cas.16320
|
2 |
Asmaa M. Zahran, Helal F. Hetta, Amal Rayan, Abeer Sharaf Eldin, Elham Ahmed Hassan, Hussein Fakhry, Ahmed Soliman, Omnia El-Badawy. Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes. Cancer Immunology, Immunotherapy 2020; 69(7): 1253 doi: 10.1007/s00262-019-02465-y
|
3 |
Ho-Sung Lee, In-Hee Lee, Sang-In Park, Minho Jung, Seung Gu Yang, Tae-Wook Kwon, Dae-Yeon Lee, Bashar Saad. Investigation of Anti-Liver Cancer Activity of the Herbal Drug FDY003 Using Network Pharmacology. Evidence-Based Complementary and Alternative Medicine 2022; 2022: 1 doi: 10.1155/2022/5765233
|
4 |
Masakazu Katsura, Fumihiro Shoji, Tatsuro Okamoto, Shinichiro Shimamatsu, Fumihiko Hirai, Gouji Toyokawa, Yosuke Morodomi, Tetsuzo Tagawa, Yoshinao Oda, Yoshihiko Maehara. Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph‐node‐positive lung cancer patients. Cancer Science 2018; 109(1): 154 doi: 10.1111/cas.13422
|
5 |
Keywan Mortezaee. Human hepatocellular carcinoma: Protection by melatonin. Journal of Cellular Physiology 2018; 233(10): 6486 doi: 10.1002/jcp.26586
|
6 |
Laura Fantuzzi, Maria Tagliamonte, Maria Cristina Gauzzi, Lucia Lopalco. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cellular and Molecular Life Sciences 2019; 76(24): 4869 doi: 10.1007/s00018-019-03255-6
|
7 |
Tong Lin, Zhimei Lin, Peipei Mai, E Zhang, Lisheng Peng. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma. Aging 2021; 13(8): 11786 doi: 10.18632/aging.202876
|
8 |
Yurie Kogue, Hiroyasu Kobayashi, Yutaka Nakamura, Takatsugu Takano, Chihiro Furuta, Osamu Kawano, Taro Yasuma, Tadashi Nishimura, Corina N. D’Alessandro-Gabazza, Hajime Fujimoto, Esteban C. Gabazza, Tetsu Kobayashi, Ichiro Fukai. Prognostic Value of CXCL12 in Non-Small Cell Lung Cancer Patients Undergoing Tumor Resection. Pharmaceuticals 2023; 16(2): 255 doi: 10.3390/ph16020255
|
9 |
Monika Gudowska-Sawczuk, Jacek Kudelski, Barbara Mroczko. The Role of Chemokine Receptor CXCR3 and Its Ligands in Renal Cell Carcinoma. International Journal of Molecular Sciences 2020; 21(22): 8582 doi: 10.3390/ijms21228582
|
10 |
Maira Afzal, Amjad Ali, Nadeem Sheikh, Shazia Rafique, Muhammad Idrees. Peripheral Expression ofCXCL10Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, and Ribavirin. Journal of Interferon & Cytokine Research 2020; 40(6): 301 doi: 10.1089/jir.2019.0185
|
11 |
Tung Nguyen Thanh Uong, Mee Sun Yoon, Kyung-Hwa Lee, Hoon Hyun, Taek-Keun Nam, Jung-Joon Min, Huy Phuoc Quang Nguyen, Sang-Ki Kim. Live cell imaging of highly activated natural killer cells against human hepatocellular carcinoma in vivo. Cytotherapy 2021; 23(9): 799 doi: 10.1016/j.jcyt.2020.11.004
|
12 |
Tong Lin, Yingzhao Zhang, Zhimei Lin, Lisheng Peng. ZWINT is a Promising Therapeutic Biomarker Associated with the Immune Microenvironment of Hepatocellular Carcinoma. International Journal of General Medicine 2021; : 7487 doi: 10.2147/IJGM.S340057
|
13 |
Hui-Ying Ma, Xin-Zhou Liu, Chun-Min Liang. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. World Journal of Gastroenterology 2016; 22(29): 6619-6628 doi: 10.3748/wjg.v22.i29.6619
|
14 |
M. V. Novikova, N. V. Khromova, P. B. Kopnin. Components of the hepatocellular carcinoma microenvironment and their role in tumor progression. Biochemistry (Moscow) 2017; 82(8): 861 doi: 10.1134/S0006297917080016
|
15 |
Xiaolei Jiao, Guiming Shu, Hui Liu, Qin Zhang, Zhe Ma, Chaoyi Ren, Hongsheng Guo, Jingxiang Shi, Junguo Liu, Chuanshan Zhang, Yijun Wang, Yingtang Gao. The Diagnostic Value of Chemokine/Chemokine Receptor Pairs in Hepatocellular Carcinoma and Colorectal Liver Metastasis. Journal of Histochemistry & Cytochemistry 2019; 67(5): 299 doi: 10.1369/0022155418824274
|
16 |
Dhatri Madduru, Johny Ijaq, Sujata Dhar, Saumyadip Sarkar, Naresh Poondla, Partha S. Das, Silvia Vasquez, Prashanth Suravajhala. Systems Challenges of Hepatic Carcinomas: A Review. Journal of Clinical and Experimental Hepatology 2019; 9(2): 233 doi: 10.1016/j.jceh.2018.05.002
|
17 |
Xiaoming Zhang, Chundi Gao, Lijuan Liu, Chao Zhou, Cun Liu, Jia Li, Jing Zhuang, Changgang Sun. DNA methylation‐based diagnostic and prognostic biomarkers of nonsmoking lung adenocarcinoma patients. Journal of Cellular Biochemistry 2019; 120(8): 13520 doi: 10.1002/jcb.28627
|
18 |
Yue Zhao, Jiaxu Wang, Wai Nam Liu, Shin Yie Fong, Timothy Wai Ho Shuen, Min Liu, Sarah Harden, Sue Yee Tan, Jia Ying Cheng, Wilson Wei Sheng Tan, Jerry Kok Yen Chan, Cheng Ean Chee, Guan Huei Lee, Han Chong Toh, Seng Gee Lim, Yue Wan, Qingfeng Chen. Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model. Hepatology 2021; 74(3): 1395 doi: 10.1002/hep.31812
|
19 |
Tong Lin, E Zhang, Pei-pei Mai, Ying-zhao Zhang, Xiang Chen, Li-sheng Peng. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. Bioscience Reports 2021; 41(6) doi: 10.1042/BSR20204312
|
20 |
Lifeng Wang, Fu-Sheng Wang. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatology International 2019; 13(5): 521 doi: 10.1007/s12072-019-09967-y
|
21 |
Mudassier Ahmad, Anupam Dhasmana, Prateek Suresh Harne, Asif Zamir, Bilal Bin Hafeez. Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?. Seminars in Cancer Biology 2022; 86: 1175 doi: 10.1016/j.semcancer.2022.02.015
|
22 |
Juliana Sobral Barros, Talita Ferreira Marques Aguiar, Silvia Souza Costa, Maria Prates Rivas, Monica Cypriano, Silvia Regina Caminada Toledo, Estela Maria Novak, Vicente Odone, Lilian Maria Cristofani, Dirce Maria Carraro, Isabela Werneck da Cunha, Cecília Maria Lima Costa, Angela M. Vianna-Morgante, Carla Rosenberg, Ana Cristina Victorino Krepischi. Copy Number Alterations in Hepatoblastoma: Literature Review and a Brazilian Cohort Analysis Highlight New Biological Pathways. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.741526
|
23 |
Satyamaheshwar Peddibhotla, Paul M. Hershberger, R. Jason Kirby, Eliot Sugarman, Patrick R. Maloney, E. Hampton Sessions, Daniela Divlianska, Camilo J. Morfa, David Terry, Anthony B. Pinkerton, Layton H. Smith, Siobhan Malany. Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma. Bioorganic & Medicinal Chemistry Letters 2020; 30(4): 126899 doi: 10.1016/j.bmcl.2019.126899
|
24 |
Susanne Feder, Astrid Bruckmann, Nichole McMullen, Christopher J. Sinal, Christa Buechler. Chemerin Isoform-Specific Effects on Hepatocyte Migration and Immune Cell Inflammation. International Journal of Molecular Sciences 2020; 21(19): 7205 doi: 10.3390/ijms21197205
|
25 |
Feng-Jiao Wang, Peng Wang, Lian-Yu Chen, Ya-Wen Geng, Hao Chen, Zhi-Qiang Meng, Lu-Ming Liu, Zhen Chen. TAM Infiltration Differences in “Tumor-First” and “ZHENG-First” Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer. Integrative Cancer Therapies 2018; 17(3): 707 doi: 10.1177/1534735418771193
|
26 |
Pooya Torkian, Maryam Haghshomar, Khashayar Farsad, Stephanie Wallace, Jafar Golzarian, Shamar J. Young. Cancer Immunology: Impact of Radioembolization of Hepatocellular Carcinoma on Immune Response Modulation. American Journal of Roentgenology 2023; 220(6): 863 doi: 10.2214/AJR.22.28800
|
27 |
Ke-Hsun Hsu, Chin-Wen Wei, Yi-Ru Su, Tung Chou, Yueh-Ling Lin, Fu-Chen Yang, Ann-Ping Tsou, Chia-lin Hsu, Ping-Hui Tseng, Nien-Jung Chen, Kuo-Shyang Jeng, Chuen-Miin Leu. Upregulation of RelB in the miR-122 knockout mice contributes to increased levels of proinflammatory chemokines/cytokines in the liver and macrophages. Immunology Letters 2020; 226: 22 doi: 10.1016/j.imlet.2020.06.015
|
28 |
Yuan Zhuang, Xiaomei Zhao, Baoying Yuan, Zhaochong Zeng, Yixing Chen. Blocking the CCL5–CCR5 Axis Using Maraviroc Promotes M1 Polarization of Macrophages Cocultured with Irradiated Hepatoma Cells. Journal of Hepatocellular Carcinoma 2021; : 599 doi: 10.2147/JHC.S300165
|
29 |
Arshi Khanam, Alip Ghosh, Joel V. Chua, Shyam Kottilil. Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathways. Journal of Translational Medicine 2023; 21(1) doi: 10.1186/s12967-023-04104-8
|
30 |
Burcu Sengez, Brian I. Carr, Hani Alotaibi. EMT and Inflammation: Crossroads in HCC. Journal of Gastrointestinal Cancer 2023; 54(1): 204 doi: 10.1007/s12029-021-00801-z
|
31 |
Chun-I Wang, Pei-Ming Chu, Yi-Li Chen, Yang-Hsiang Lin, Cheng-Yi Chen. Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC. International Journal of Molecular Sciences 2021; 22(24): 13627 doi: 10.3390/ijms222413627
|
32 |
Xiongfeng Pan, Atipatsa C Kaminga, Shi Wu Wen, Aizhong Liu. Chemokines in hepatocellular carcinoma: a meta-analysis. Carcinogenesis 2020; 41(12): 1682 doi: 10.1093/carcin/bgaa106
|
33 |
Chen Chen, Qi-di Ai, Yu-hui Wei. Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux. Journal of Ethnopharmacology 2021; 264: 113388 doi: 10.1016/j.jep.2020.113388
|
34 |
Gabriela M. Wiedemann, Natascha Röhrle, Marie-Christine Makeschin, Julia Fesseler, Stefan Endres, Doris Mayr, David Anz. Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate. Pathology 2019; 51(6): 586 doi: 10.1016/j.pathol.2019.06.001
|
35 |
Wufeng Fan, Guangming Ye. Microarray analysis for the identification of specific proteins and functional modules involved in the process of hepatocellular carcinoma originating from cirrhotic liver. Molecular Medicine Reports 2018; doi: 10.3892/mmr.2018.8555
|
36 |
Gang Yuan, Bin Chen, Yina Meng, Jialin Lu, Xiaojun Shi, Airong Hu, Yaoren Hu, Donghui Wang. Role of the CXCR3‑mediated TLRs/MyD88 signaling pathway in promoting the development of hepatitis B into cirrhosis and liver cancer. Molecular Medicine Reports 2021; 24(4) doi: 10.3892/mmr.2021.12378
|
37 |
Amani Makkouk, Xue (Cher) Yang, Taylor Barca, Anthony Lucas, Mustafa Turkoz, Jonathan T S Wong, Kevin P Nishimoto, Mary M Brodey, Maryam Tabrizizad, Smitha R Y Gundurao, Lu Bai, Arun Bhat, Zili An, Stewart Abbot, Daulet Satpayev, Blake T Aftab, Marissa Herrman. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer 2021; 9(12): e003441 doi: 10.1136/jitc-2021-003441
|
38 |
Jiaqi Yang, David Sontag, Yuewen Gong, Gerald Y. Minuk. Alterations in chemokine receptor CCR5 activity influence tumor cell biology in human cholangiocarcinoma cell lines. Annals of Hepatology 2021; 21: 100265 doi: 10.1016/j.aohep.2020.09.009
|